Select ongoing novel chimeric antigen receptor T-cell trials
| Target . | Phase . | Identifier . | Additional agents . |
|---|---|---|---|
| CD19/CD20 | 1 | NCT04215016 NCT04007029 | |
| CD19/CD22 | 1 | NCT03233854 | |
| CD19/CD22 | 1/2 | NCT03287817 | Followed by PD-1 antibody pembrolizumab |
| CD19 | 1 | NCT02706405 | Followed by PD-1 antibody durvalumab |
| CD19 | 1/2 | NCT04257578 | BTK inhibitor acalabrutinib prior |
| CD20 | 1/2 | NCT03277729 | |
| CD22 | 1 | NCT04088890 |
| Target . | Phase . | Identifier . | Additional agents . |
|---|---|---|---|
| CD19/CD20 | 1 | NCT04215016 NCT04007029 | |
| CD19/CD22 | 1 | NCT03233854 | |
| CD19/CD22 | 1/2 | NCT03287817 | Followed by PD-1 antibody pembrolizumab |
| CD19 | 1 | NCT02706405 | Followed by PD-1 antibody durvalumab |
| CD19 | 1/2 | NCT04257578 | BTK inhibitor acalabrutinib prior |
| CD20 | 1/2 | NCT03277729 | |
| CD22 | 1 | NCT04088890 |
BTK, Bruton’s tyrosine kinase inhibitor; PD-1, programmed death 1.